Evidence map›Paper›PMID 39539567›Full record

ArticleBJUI compass2024

Reduced p63 expression is linked to unfavourable prognosis in muscle-invasive urothelial carcinoma of the bladder.

Kira Furlano, Henning Plage, Sebastian Hofbauer, Sarah Weinberger, Bernhard Ralla, Annika Fendler, Florian Roßner, Simon Schallenberg, Sefer Elezkurtaj, Martina Kluth and 19 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJUI compass, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Erratum.BJUI compass · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Kira FurlanoDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Henning PlageDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.ORCID https://orcid.org/0000-0002-7680-1870
Sebastian HofbauerDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Sarah WeinbergerDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Bernhard RallaDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Annika FendlerDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Florian RoßnerInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Simon SchallenbergInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Sefer ElezkurtajInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Martina KluthInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Maximilian LennartzInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Niclas C BlessinInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Andreas H MarxDepartment of Pathology Academic Hospital Fuerth Fuerth Germany.
Henrik SamtlebenDepartment of Pathology Academic Hospital Fuerth Fuerth Germany.
Margit FischDepartment of Urology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Michael RinkDepartment of Urology Marienhospital Hamburg Hamburg Germany.
Marcin SlojewskiDepartment of Urology and Urological Oncology Pomeranian Medical University Szczecin Poland.
Krystian KaczmarekDepartment of Urology and Urological Oncology Pomeranian Medical University Szczecin Poland.
Thorsten EckeDepartment of Urology Helios Hospital Bad Saarow Bad Saarow Germany.
Stefan KochDepartment of Pathology Helios Hospital Bad Saarow Bad Saarow Germany.
Nico AdaminiDepartment of Urology Albertinen Hospital Hamburg Germany.
Sarah MinnerInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Ronald SimonInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.ORCID https://orcid.org/0000-0003-0158-4258
Guido SauterInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Joachim WeischenfeldtDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Tobias KlatteDepartment of Urology Helios Hospital Bad Saarow Bad Saarow Germany.ORCID https://orcid.org/0000-0002-4392-6861
Thorsten SchlommDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
David HorstInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Henrik ZechaDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: There is a shortage of established prognostic biomarkers in bladder cancer. One candidate is tumour protein 63 (p63), a transcription factor of the p53 gene family that is expressed in the normal urothelium. Recently proposed RNA expression-based molecular classifiers of bladder cancer identified high p63 expression as a component of a basal/squamous subtype linked to poor patient prognosis. Methods: In this study, p63 protein expression was analysed by immunohistochemistry on more than 2500 urothelial bladder carcinomas in a tissue microarray format to determine its relationship with clinicopathological parameters of disease progression and patient outcome. Results: Nuclear p63 staining was seen in all cells of normal urothelium and at elevated levels in pTaG2 tumours. The rate of p63 positive cases and the staining intensity was lower in pTaG3 tumours (93.2%, Conclusion: The independent prognostic role of reduced p63 expression in advanced urothelial carcinomas suggests that p63 could be a useful biomarker to distinguish pT2-4 urothelial carcinomas.

Indexed as

biomarkerimmunohistochemistryp63tissue microarrayurothelial carcinoma

Identifiers

PMID39539567
PMCPMC11557268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.